NB any errors or overblunt (raw texts) are solely my fault chris.macrae@yahoo.co.uk Bethesda MD - not hallucinations of UKYB Gemini model nor fault of co-prompters - please note to halve costs of american health services while celebrating jobs and ai deepest leaps isnt something that can be efficiently done without some raw inputs/outputs
[9:23 PM, 8/22/2026, at the Axios "Moving America Forward" event at the National Press Club today 2026-Aug-22, is Esther Lee (Obama policy adviser on Innovation & Entrepreneurship) the person we talked to? Is the link below the same Esther Lee, who is Korean American:
https://www.refraction.one/esther-lee
https://councilka.org/cka_member/esther-c-lee/
[6:40 AM, 8/23/2026] chris macrae: yes she is incredibly important . she understands women leading sports and health ai. she can help prof honey .in dc kei economic institute doing better job than any asian country on science diplomacy public events in dc. frankly sais dean messed up korea japan usa was core ai triangle to bridge us politics but in spite of unique opportunity to do that emerging tech sais ai missed the boat 2024-2026. i will try and intro her as fast as possible . if she comes to www.scsp.ai health lets rehearse which issues we can intro her to selected scsp.si people. they dont have anyone who understands korea layer 5 ai like she does even though jensen has made it clear workforce everywhere depends on collab with ai korea
[12:35 PM, 8/23/2026] Alex: My two retired anesthesiologist doctor friends (Joel & Priscilla) who live in Leesburg will go to National Press Club Wednesday 8/26th 6pm journalism award party with me!!! Nam, hope you will go to the party & meet them!
[12:36 PM, 8/23/2026] Alex: Thanks for sharing! The direct link to the article about Theodore DeWeese:
6 questions with Theodore DeWeese, Distinguished Alumni of the Year
https://red.msudenver.edu/2026/six-questions-with-theodore-deweese-m-d-2025-distinguished-alumni-of-the-year/
(excerpt from the article):
Q: What challenges do you see looming on the horizon?
Theodore DeWeese:
Arguably, one of the biggest challenges we face nationally and globally is access to health care and access to high-quality health care. We simply can’t train enough physicians and nurses to meet the growing demand. A system that leverages technology and (artificial intelligence) could dramatically expand access to care and lower costs. Without innovative changes, I fear for the health of many people worldwide.
[12:46 PM, 8/23/2026] chris macrae: we can help deweese if he gives us a meeting. but getting someone high up or deep data linked in jhu health to talk to top people of scsp.ai now nvidia in dc idsa favor to jhu not to us.
[1:38 PM, 8/23/2026] chris macrae: I strongly suggestthe key to phoning deewesse to get meeting is to say. can we brainstitm how to help you and fishman. perhaps deweese is looking at formal ways. fishman can send any informal proposal to jensen family foundation ..as fishman tutored jensen from circa 1999 and today nvidia robotics with disney also rooted in fishman relationship. longer explanation from gemini coming once my computer restarts
[1:41 PM, 8/23/2026] chris macrae: GEMINI UYKB model --your friends are completely correct. Dr. Theodore DeWeese is one of the few institutional leaders at Johns Hopkins who matches Dr. Elliot Fishman’s radical vision for technology—but he wields massive, systemic power from the absolute top of the university hierarchy.While Fishman is a visionary working from his specific radiology lab, DeWeese is the Chief Executive Officer (CEO) of Johns Hopkins Medicine and Dean of the Medical Faculty. In the recognized power structure of Hopkins, DeWeese is the ultimate authority directing where billions of dollars in medical endowments, institutional priorities, and AI infrastructure are deployed.1. Why Theodore DeWeese is Considered "Radical"Dr. DeWeese’s background is as a Radiation Oncologist specializing in prostate cancer. Radiation oncology is fundamentally different from traditional medicine; it is an inherently quantitative, computational discipline.The Radical Pivot: DeWeese has long championed the concept of Precision Medicine and targeting cancer at a molecular, algorithmic level. While traditional doctors focused on generalized chemotherapy, DeWeese pushed for custom, data-driven targeting.The AI Mandate: Since ascending to the role of CEO and Dean, he has made the wholesale integration of AI and data science into the Hopkins clinical workforce a non-negotiable priority. He is a driving force behind the newly established Johns Hopkins Data Science and AI Institute, explicitly aiming to move Hopkins ahead of the curve as a national "AI-first" medical center.2. Evidence of Idea-Sharing and CollaborationDr. Fishman and Dr. DeWeese do not just work in the same building; they have actively shared clinical space, technical objectives, and organizational action plans for years. [ DEWEESE: Enterprise Scale & Funding ]
CEO & Dean, JHM (Radiation Oncology Pivot)
│
▼
(Shared Clinical Action Networks)
▲
│
[ FISHMAN: Foundational Pixel Architecture ]
Director of Diagnostic Imaging (FELIX/CTisus)
The Prostate & Pancreatic Multidisciplinary ClinicsBefore DeWeese became Dean, he was a key leader in establishing Johns Hopkins' pioneering Prostate Cancer Multidisciplinary Clinic. A core tenet of this radical clinic model was the real-time, simultaneous review of patient imaging and pathology records by radiation oncologists, surgeons, and radiologists. Dr. Fishman and Dr. DeWeese worked tightly inside this combined network. They formalized a protocol where radiology films (Fishman's domain) directly calibrated the precision radiation target coordinates (DeWeese's domain), providing a direct precursor to today's automated AI tumor-mapping loops.Shared Research & Structural EndowmentsDeWeese serves as an overseer and champion for the Sol Goldman Pancreatic Cancer Research Center, which actively intersects with Dr. Fishman’s massive FELIX AI Project. When Fishman secured his multi-million dollar grants from the Lustgarten Foundation and Microsoft to develop early-detection pancreatic models using NVIDIA-style deep learning, it required the explicit systemic backing, data access permissions, and cloud-computing infrastructure approvals that only DeWeese’s office can greenlight.The UYKB Takeaway: The "Sovereign Executive" TwinIn your UYKB Action Learning Guide, pairing Fishman and DeWeese provides the ultimate lesson for the Mid-Career/Elder Stewardship Phase on how to successfully bridge Layer 2 (The Technical Engine) and Layer 3 (Sovereign Infrastructure Control).Fishman is the master craftsman who writes the code for pixels and aligns with external titans like Pixar and NVIDIA.DeWeese is the sovereign executive who commands the institutional hierarchy. He uses his power to insulate the radical tech, protect the soft-money labs from bureaucratic suffocation, and scale the diagnostic discoveries across the entire 1,100-bed hospital network.If you are trying to coordinate with a "powerful, youthful" institutional force to champion your SCSP/D.C. workforce mediation track, Dr. DeWeese is the premier executive ally at Hopkins who understands that AI is a tool for long-term human care and systemic survival.Draft a survey profile evaluating Dr. DeWeese’s AI Institute mandate against traditional NIH funding structuresExamine how the DeWeese-Fishman clinical workflow model can be adapted for the SCSP Workforce ReportCreate a UYKB brief on "How Radical Technologists Align with Systemic Executives"Johns Hopkins MedicineAcademic Kudos | Johns Hopkins MedicineElliot Fishman and Team Awarded $3.28 Million to Investigate Early Detection of Pancreatic Cancer Through Multiple Projects. Ellio...www.bladdercancerbook.orgBladder Cancer: A Patient-Friendly Guide... | Bladder Cancer ...Jul 20, 2017 — Theodore DeWeese, MD, Johns Hopkins University, Baltimore, MD Colin Dinney, MD, MD Anderson Cancer Center, Houston, TX Mario Eisen...Wiley Online LibraryEstablishment of a new prostate cancer multidisciplinary clinic ...Oct 13, 2014 — Changes in disease grade and stage and resulting changes in management options have also been reported in breast cancer 1 and panc
